Jubilant Generics Profile
Key Indicators
- Authorised Capital ₹ 3.00 Cr
as on 23-10-2024
- Paid Up Capital ₹ 2.58 Cr
as on 23-10-2024
- Company Age 11 Year, 24 Days
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 500.00 Cr
as on 23-10-2024
- Satisfied Charges ₹ 810.00 Cr
as on 23-10-2024
- Revenue -74.67%
(FY 2023)
- Profit -1618.59%
(FY 2023)
- Ebitda -196.88%
(FY 2023)
- Net Worth -53.06%
(FY 2023)
- Total Assets -49.95%
(FY 2023)
About Jubilant Generics
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 3.00 Cr and a paid-up capital of Rs 2.58 Cr.
The company currently has active open charges totaling ₹500.00 Cr. The company has closed loans amounting to ₹810.00 Cr, as per Ministry of Corporate Affairs (MCA) records.
The Key Managerial Personnel (KMP) at Jubilant Generics Limited India are Jaidev Rajpal as CEO and Shikha Aggarwal as Cfo. Shirish Belapure, Jasdeepsingh Sood, Arvind Chokhany, and Two other members serve as directors at the Company.
- CIN/LLPIN
U24100UP2013FLC060821
- Company No.
060821
- Company Classification
Public Limited Foreign Company Incorporated In India
- Incorporation Date
25 Nov 2013
- Date of AGM
29 Aug 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Kanpur
Industry
Company Details
- Location
Ghaziabad, Uttar Pradesh, India
- Telephone
- Email Address
- Website
- Social Media-
What products or services does Jubilant Generics Limited offer?
Jubilant Generics Limited offers a wide range of products and services, including Skin Care, Sanitizers & Handwash.
Who are the key members and board of directors at Jubilant Generics?
Executive Team (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Jaidev Rajpal  | Managing Director | 11-Oct-2022 | Current |
| Shikha Aggarwal | CFO | 01-Aug-2024 | Current |
Board Members(4)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Shirish Belapure | Additional Director | 15-Jul-2024 | Current |
| Jasdeepsingh Sood | Whole-Time Director | 14-May-2019 | Current |
| Gayatri Taragi | Additional Director | 19-Jun-2024 | Current |
| Arvind Chokhany | Director | 03-Jun-2021 | Current |
Financial Performance and Corporate Structure Insights of Jubilant Generics.
Jubilant Generics Limited, for the financial year ended 2023, experienced significant reduction in revenue, with a 74.67% decrease. The company also saw a substantial fall in profitability, with a 1618.59% decrease in profit. The company's net worth observed a substantial decline by a decrease of 53.06%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Jubilant Generics?
In 2022, Jubilant Generics had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Jubilant Biosys LimitedActive 26 years 10 monthsArvind Chokhany and Gayatri Taragi are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 09 Jan 2015 | ₹500.00 Cr | Open |
Indusind Bank Ltd. Creation Date: 05 Feb 2016 | ₹100.00 Cr | Satisfied |
Il & Fs Trust Company Limited Creation Date: 30 Sep 2014 | ₹130.00 Cr | Satisfied |
How Many Employees Work at Jubilant Generics?
Jubilant Generics has a workforce of 1106 employees as of Apr 06, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Jubilant Generics, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Jubilant Generics's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
